This product is a nitroimidazole derivative that can inhibit the redox reaction of amoeba and break the nitrogen chain of the protozoa. In vitro tests have shown that when the drug concentration is 1~2mg/L, the histolytica amoeba can undergo morphological changes in 6~20 hours and all are killed within 24 hours. When the concentration is 0.2mg/L, the histolytica amoeba can be killed within 72 hours. This product has a strong effect of killing trichomonas, and its mechanism is unknown. Metronidazole has a killing effect on anaerobic microorganisms, and the metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial deoxyribonucleic acid, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death. It has a carcinogenic effect on some animals.

It inhibits the synthesis and release of prostaglandins in the hypothalamus, restores the normal responsiveness of the receptor neurons in the body temperature regulation center, and has an antipyretic effect; it has an analgesic effect by inhibiting the synthesis of prostaglandins, etc.; it inhibits the synthesis and release of prostaglandins in local inflammatory tissues, stabilizes lysosomal enzymes, and affects the phagocytic function of macrophages, thereby playing an anti-inflammatory role.

It inhibits the synthesis and release of prostaglandins in the hypothalamus, restores the normal responsiveness of the receptor neurons in the body temperature regulation center, and has an antipyretic effect; it has an analgesic effect by inhibiting the synthesis of prostaglandins, etc.

It is a central nervous system stimulant that can excite the cerebral cortex, increase sensitivity to the outside world, constrict cerebral blood vessels, and enhance the effect of the first two drugs in relieving headaches.

It has sedative, hypnotic and anticonvulsant effects, can enhance the analgesic effect of aminopyrine and phenacetin, and prevent convulsions caused by fever.

This product is a synthetic antibacterial anti-tuberculosis drug. It has strong activity against bacteria in the growth and reproduction stage, and has almost no effect on bacteria in the dormant stage. It has high antibacterial activity against various types of mycobacteria. There is no cross-resistance between Mycobacterium tuberculosis and this product and other drugs. It may inhibit the metabolism of sensitive bacteria, inhibit RNA synthesis, and interfere with the protein metabolism of Mycobacterium tuberculosis, thereby causing bacterial death. In large doses, it can cause cleft palate, brain exposure, and spinal deformity in mouse experiments; it can cause mild cervical deformity in rat experiments; it can cause cyclops, short limbs, and cleft palate in rabbit experiments.

This product is an anticholinergic drug that can significantly relieve gastrointestinal smooth muscle spasm.

This product is a broad-spectrum antibacterial agent with bactericidal effect at high concentrations. In addition to common Gram-positive bacteria, Gram-negative bacteria and anaerobic bacteria, most Rickettsia, Mycoplasma, Chlamydia, atypical mycobacteria and spirochetes are also sensitive to this product. This product is better than Gram-positive bacteria for Gram-negative bacteria, but Enterococcus is resistant to it. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, etc. are sensitive to this product. This product has certain antibacterial activity against Neisseria gonorrhoeae, but penicillin-resistant gonococci are also resistant to tetracycline. This product has good antibacterial effect on Gram-negative bacteria such as Vibrio, Yersinia pestis, Brucella, Campylobacter, Yersinia, etc., has no antibacterial activity against Pseudomonas aeruginosa, and has certain antibacterial effect on some anaerobic bacteria, but it is far inferior to metronidazole, clindamycin and chloramphenicol, so it is not used clinically. Due to the widespread use of tetracyclines over the years, most common clinical pathogens, including Gram-positive bacteria such as Staphylococcus and Gram-negative bacteria such as Enterobacter, are resistant to tetracyclines, and there is cross-resistance between similar species. The mechanism of action of this product is that the drug can specifically bind to the A position of the 30S subunit of the bacterial ribosome, preventing the binding of aminoacyl-tRNA at this position, thereby inhibiting the growth of peptide linkages and affecting the synthesis of bacterial proteins.